Furthermore, PCs activated by cancer cells can also inhibit anti-tumor immune responses by downregulating the expression of CD80, CD86 co-stimulatory molecules and MHC-II, as well as upregulating the expression of PD-L1 [294, 295]. This evidence concerns the gene CD274 and cancer.